Press Releases Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX Other stock markets 03:46:37 2024-04-29 pm EDT			5-day change	1st Jan Change
8.745 ^USD	+3.25%		-2.24%	+170.59%

Apr. 10	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
Mar. 18	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcutis Appoints David Topper as Chief Financial Officer	Apr. 10	GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	AQ
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	Apr. 01	AQ
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	Mar. 28	AQ
Arcutis Promotes Todd Tucker to Chief Human Resources Officer	Mar. 11	GL
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	Mar. 10	AQ
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	Mar. 10	GL
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	Mar. 09	AQ
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	Mar. 09	GL
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 06	AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 05	AQ
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	Mar. 04	GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	Mar. 04	GL
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	Mar. 04	AQ
Arcutis Biotherapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Mar. 01	AQ
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 29	AQ
Arcutis Announces Pricing of $150 Million Public Offering	Feb. 28	GL
Arcutis Announces Proposed Public Offering	Feb. 28	GL
Arcutis Announces Proposed Public Offering	Feb. 28	AQ
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan	Feb. 28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Press Releases

Filters